BIOGEN INC (BIIB)
US09062X1037 - Common Stock
Taking everything into account, BIIB scores 5 out of 10 in our fundamental rating. BIIB was compared to 565 industry peers in the Biotechnology industry. BIIB scores excellent on profitability, but there are some minor concerns on its financial health. BIIB is cheap, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BIIB was profitable.
In the past year BIIB had a positive cash flow from operations.
BIIB had positive earnings in each of the past 5 years.
In the past 5 years BIIB always reported a positive cash flow from operatings.
1.2 Ratios
BIIB has a better Return On Assets (5.70%) than 95.37% of its industry peers.
With an excellent Return On Equity value of 9.87%, BIIB belongs to the best of the industry, outperforming 95.01% of the companies in the same industry.
BIIB has a better Return On Invested Capital (9.36%) than 95.01% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIIB is below the industry average of 15.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| ROIC | 9.36% |
ROA(3y)7.75%
ROA(5y)12.23%
ROE(3y)14.96%
ROE(5y)25.28%
ROIC(3y)12.12%
ROIC(5y)17.18%
1.3 Margins
BIIB's Profit Margin of 16.81% is amongst the best of the industry. BIIB outperforms 96.26% of its industry peers.
BIIB's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 25.92%, BIIB belongs to the top of the industry, outperforming 96.61% of the companies in the same industry.
In the last couple of years the Operating Margin of BIIB has declined.
BIIB has a Gross Margin of 75.59%. This is amongst the best in the industry. BIIB outperforms 85.38% of its industry peers.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.92% | ||
| PM (TTM) | 16.81% | ||
| GM | 75.59% |
OM growth 3Y-15.78%
OM growth 5Y-14.65%
PM growth 3Y-26.52%
PM growth 5Y-18.55%
GM growth 3Y-4.45%
GM growth 5Y-2.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BIIB is creating some value.
BIIB has more shares outstanding than it did 1 year ago.
BIIB has less shares outstanding than it did 5 years ago.
BIIB has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.83 indicates that BIIB is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.83, BIIB is doing good in the industry, outperforming 73.62% of the companies in the same industry.
BIIB has a debt to FCF ratio of 3.56. This is a good value and a sign of high solvency as BIIB would need 3.56 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.56, BIIB belongs to the top of the industry, outperforming 94.30% of the companies in the same industry.
A Debt/Equity ratio of 0.28 indicates that BIIB is not too dependend on debt financing.
BIIB has a worse Debt to Equity ratio (0.28) than 70.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 3.56 | ||
| Altman-Z | 2.83 |
ROIC/WACC0.94
WACC9.96%
2.3 Liquidity
A Current Ratio of 1.26 indicates that BIIB should not have too much problems paying its short term obligations.
BIIB's Current ratio of 1.26 is on the low side compared to the rest of the industry. BIIB is outperformed by 84.49% of its industry peers.
A Quick Ratio of 0.80 indicates that BIIB may have some problems paying its short term obligations.
BIIB has a worse Quick ratio (0.80) than 89.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.8 |
3. Growth
3.1 Past
BIIB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.16%.
BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -10.49% yearly.
BIIB shows a decrease in Revenue. In the last year, the revenue decreased by -3.86%.
The Revenue has been decreasing by -6.07% on average over the past years.
EPS 1Y (TTM)3.16%
EPS 3Y-22.83%
EPS 5Y-10.49%
EPS Q2Q%-6.42%
Revenue 1Y (TTM)-3.86%
Revenue growth 3Y-9.9%
Revenue growth 5Y-6.07%
Sales Q2Q%-2.54%
3.2 Future
The Earnings Per Share is expected to grow by 9.06% on average over the next years. This is quite good.
Based on estimates for the next years, BIIB will show a small growth in Revenue. The Revenue will grow by 1.55% on average per year.
EPS Next Y10.97%
EPS Next 2Y6.17%
EPS Next 3Y5.99%
EPS Next 5Y9.06%
Revenue Next Year-2.95%
Revenue Next 2Y-2.25%
Revenue Next 3Y-0.93%
Revenue Next 5Y1.55%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BIIB is valuated reasonably with a Price/Earnings ratio of 9.80.
98.04% of the companies in the same industry are more expensive than BIIB, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BIIB to the average of the S&P500 Index (28.53), we can say BIIB is valued rather cheaply.
With a Price/Forward Earnings ratio of 9.41, the valuation of BIIB can be described as very reasonable.
BIIB's Price/Forward Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 98.22% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.40. BIIB is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.8 | ||
| Fwd PE | 9.41 |
4.2 Price Multiples
97.86% of the companies in the same industry are more expensive than BIIB, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BIIB is valued cheaply inside the industry as 98.04% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.18 | ||
| EV/EBITDA | 9.17 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)0.89
PEG (5Y)N/A
EPS Next 2Y6.17%
EPS Next 3Y5.99%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOGEN INC
NASDAQ:BIIB (11/15/2024, 8:00:00 PM)
After market: 159.99 0 (0%)159.99
-4.9 (-2.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap23.31B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.8 | ||
| Fwd PE | 9.41 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.89
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 25.92% | ||
| PM (TTM) | 16.81% | ||
| GM | 75.59% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)3.16%
EPS 3Y-22.83%
EPS 5Y
EPS Q2Q%
EPS Next Y10.97%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-3.86%
Revenue growth 3Y-9.9%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y